| Literature DB >> 25972740 |
P V Khachane1, A S Jain1, V V Dhawan1, G V Joshi2, A A Date3, R Mulherkar2, M S Nagarsenker1.
Abstract
Successful cytosolic delivery enables opportunities for improved treatment of various genetic disorders, infectious diseases and cancer. Cationic nanoemulsions were designed using alternative excipients and evaluated for particle size, charge, effect of sterilization on its stability, DNA condensation potential and cellular uptake efficiency. Various concentrations of non-ionic and ionic stabilizers were evaluated to design formula for colloidally stable cationic nanoemulsion. The nanoemulsion comprised of 5% Capmul MCM, 0.5% didodecyldimethylammonium bromide (DDAB), 1% phospholipid, 1% Poloxamer 188 and 2.25% glycerol and possessed particle size of 81.6 ± 3.56 nm and 137.1 ± 1.57 nm before and after steam sterilization, respectively. DNA condensation studies were carried out at various nanoemulsion: DNA ratios ranging from 1:1 to 10:1. Cell uptake studies were conducted on human embryonic kidney (HEK) cell lines which are widely reported for transfection studies. The nanoemulsions showed excellent cellular uptake as evaluated by fluorescence microscopy and flow cytometry. Overall, a colloidally stable cationic nanoemulsion with good DNA condensation ability was successfully fabricated for efficient cytosolic delivery and potential for in vivo effectiveness.Entities:
Keywords: Cationic; Cytosolic delivery; Didodecyldimethylammonium bromide; Intracellular delivery; Nanoemulsion
Year: 2014 PMID: 25972740 PMCID: PMC4421023 DOI: 10.1016/j.jsps.2014.07.007
Source DB: PubMed Journal: Saudi Pharm J ISSN: 1319-0164 Impact factor: 4.330
Figure 1Schematic of cationic nanoemulsion formulation and condensation with DNA.
Formula of cationic nanoemulsion.
| Ingredients | Proposed use | %w/v (prototype formula) | %w/v (optimized final formula) |
|---|---|---|---|
| Capmul MCM | Oil phase | 5 | 5 |
| Poloxamer 188 | Impart better stabilization | 1 | 1 |
| DDAB | Impart positive charge | 0.5 | 0.5 |
| PL 90 H | Impart Thermal stability | 0.5 | 1 |
| Glycerol | Impart isoosmolarity | 2.25 | 2.25 |
| Water | Vehicle | q.s. 10 gms | q.s. 10 gms |
Particle size analysis of batches S1-S9.
| Formulation | Before sterilization | After autoclaving | Other observations | ||
|---|---|---|---|---|---|
| M.P.S. | P.I. | M.P.S. | P.I. | ||
| Prototype formula (S1) | 73.2 ± 9.21 | 0.709 ± 0.053 | 111.7 ± 3.28 | 0.524 ± 0.126 | Not stable for long after autoclaving |
| S2 | 108.3 ± 2.07 | 0.963 ± 0.046 | NS | NS | Oil globules seen under microscope |
| S3 | 101.0 ± 1.67 | 0.615 ± 0.002 | NS | NS | Same as S2 |
| S4 | 95.3 ± 1.15 | 0.951 ± 0.004 | NS | NS | Same as S2 |
| S5 | 65.5 ± 1.54 | 0.839 ± 0.048 | NS | NS | Same as S2 |
| S6 | 70.2 ± 1.94 | NS | NS | NS | Same as S2 |
| S7 | 87.0 ± 3.83 | NS | NS | NS | Same as S2 |
| S8 | 72.3 ± 5.69 | NS | NS | NS | Same as S2 |
| S9 | 81.6 ± 3.56 | 0.767 ± 0.18 | 137.1 ± 1.57 | 0.210 ± 0.042 | M.P.S. 6 h after autoclaving: 143.1 ± 5.11; P.I.: 0.271 ± 0.166 |
M.P.S.: Mean particle size; P.I.: Polydispersity index; NS: Not satisfactory.
Figure 2DNA condensation results. Lane 1 shows naked DNA whereas absence of bands on the gel in Lane 2, 3 and 4 indicates complete condensation between the DNA and the delivery system.
Figure 3Fluorescence images of HEK cells (A) and (B) represent merged and fluorescence images of untreated control whereas (C) and (D) represent the merged and fluorescence images of nanoemulsion treated cells, respectively.
Figure 4Flow cytometry histograms of untreated control and nanoemulsion treated cells.
Compositions of batches for optimization of prototype formula.
| Formulation | Capmul MCM | Poloxamer 188 | DDAB | PL 90H |
|---|---|---|---|---|
| Prototype formula (S1) | 5 | 1 | 0.5 | 0.5 |
| S2 | 5 | 2 | 0.5 | 0.5 |
| S3 | 5 | 3 | 0.5 | 0.5 |
| S4 | 5 | 4 | 0.5 | 0.5 |
| S5 | 5 | 5 | 0.5 | 0.5 |
| S6 | 2.5 | 1 | 0.5 | 1 |
| S7 | 2.5 | 2 | 0.5 | 1 |
| S8 | 2.5 | 1 | 1 | 1 |
| Final optimized Formula (S9) | 5 | 1 | 0.5 | 1 |